Mersana Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 171.67 million compared to USD 204.21 million a year ago. Basic loss per share from continuing operations was USD 1.48 compared to USD 2.18 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.61 USD | -0.38% | -25.96% | +12.50% |
09/05 | Transcript : Mersana Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
09/05 | Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $9.2M, vs. Street Est of $8.5M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.50% | 321M | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- MRSN Stock
- News Mersana Therapeutics, Inc.
- Mersana Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023